Study guide
9.3 Management of Non-Seminoma (Stage I to Metastatic)
FEBU Part 1 Written European Board of Urology
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice
2 Chapter 2: Genitourinary Anatomy & Renal Physiology
2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance
3 Chapter 3: Urological Pharmacology & Diagnostic Imaging
3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine
4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification
4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging
5 Chapter 5: Prostate Cancer: Localized & Advanced Management
5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)
6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)
6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy
7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma
7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)
8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms
8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas
9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer
9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy
10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms
10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO
11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology
11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation
12 Chapter 12: Urolithiasis: Evaluation & Medical Management
12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy
13 Chapter 13: Endourology & Interventional Stone Management
13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety
14 Chapter 14: Infections, Andrology & Male Infertility
14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery
15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation
15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation
9.3 Management of Non-Seminoma (Stage I to Metastatic)
Key Takeaways Explain This Topic AI
Non-seminomatous germ cell tumours (NSGCTTs) comprise embryonal carcinoma, yolk sac tumour, choriocarcinoma, and teratoma; teratoma is inherently resistant to chemotherapy and radiotherapy and risks malignant somatic transformation.
In Stage I NSGCTT, the presence of lymphovascular invasion (LVI) in the primary orchiectomy specimen is the single most powerful predictor of occult retroperitoneal metastases, raising relapse risk from ~15% (LVI-negative) to ~50% (LVI-positive).
Surveillance is preferred for stage IA NSGCT when follow-up is feasible. With LVI, discuss surveillance or one adjuvant BEP cycle, which reduces relapse to about 2–3%; balance recurrence risk against acute and uncertain long-term toxicity.
The IGCCCG classification categorizes metastatic NSGCTT into Good Risk (3x BEP or 4x EP), Intermediate Risk (4x BEP), and Poor Risk (4x BEP or 4x VIP); Poor Risk is defined by a primary mediastinal origin, non-pulmonary visceral metastases, or S3 tumour markers.
After first-line chemotherapy, resect NSGCT residual retroperitoneal masses >1 cm in transaxial long axis when markers are normal or normalizing. FDG PET does not reliably distinguish teratoma from necrosis and is not recommended for restaging.
Last updated: November 2026
9.3 Management of Non-Seminoma (Stage I to Metastatic)
Non-Seminomatous Germ Cell Tumours (NSGCTTs) account for approximately 50% of all testicular malignancies and characteristically affect younger men, with a peak incidence in the third decade of life (median age 25 to 30 years) . Approximately 60% to 70% of non-seminomas present as mixed germ cell tumours containing two or more distinct histological components. Unlike seminomas, non-seminomatous neoplasms tend to be biologically more aggressive, demonstrate a higher propensity for early hematogenous and lymphatic dissemination, and frequently contain teratoma , which is entirely insensitive to cytotoxic chemotherapy and ionizing radiation.
1. Histopathological Subtypes & Somatic Transformation
Accurate histological classification dictates clinical risk stratification and therapeutic responsiveness across all stages:
Embryonal Carcinoma
Microscopic Appearance: Highly aggressive, poorly differentiated, primitive epithelioid cells with amphophilic cytoplasm, pleomorphic vesicular nuclei, prominent nucleoli, and brisk mitotic activity. They form solid sheets, papillary projections, or irregular glandular/tubular structures with extensive central geographic necrosis.
Immunohistochemistry: Strongly positive for CD30, OCT3/4, SOX2, Cytokeratin (AE1/AE3) , and SALL4; c-KIT (CD117) is negative .
Marker Secretion: May produce both AFP (if microscopic yolk sac differentiation exists) and beta-hCG .
Yolk Sac Tumour (Endodermal Sinus Tumour)
Microscopic Appearance: The most common testicular neoplasm in infants and children <3 years (pure form, excellent prognosis); in adults, it occurs almost exclusively as a component of mixed NSGCTT. Manifests in diverse patterns (reticular/microcystic, festoon, pseudopapillary). Pathognomonic Schiller-Duval bodies (a central single capillary surrounded by a mantle of cuboidal/columnar tumour cells within a microcystic space, mimicking an embryonic glomerulus) are identified in 50% to 75% of cases.
Immunohistochemistry & Markers: Strongly positive for AFP, Glypican-3 , and SALL4. Consistently responsible for marked serum AFP elevations.
Choriocarcinoma
Microscopic Appearance: Highly malignant, dimorphic population composed of multinucleated syncytiotrophoblasts (large cells with abundant vacuolated eosinophilic cytoplasm producing massive beta-hCG) intermingled with cohesive mononucleated cytotrophoblasts . The tumour is characterized by extensive, destructive vascular invasion and extensive parenchymal hemorrhage.
Clinical Behavior: Pure choriocarcinoma is exceedingly rare (<1%), but carries the most aggressive clinical course of any germ cell tumour. It bypasses retroperitoneal lymph nodes to undergo early hematogenous metastasis to lungs, liver, brain, and spleen. Massive beta-hCG elevations (>50,000 to >1,000,000 IU/L) frequently cause bilateral gynecomastia and can precipitate acute spontaneous intratumoural alveolar or intracerebral hemorrhage ( choriocarcinoma syndrome ).
Teratoma (Mature vs Immature) & Somatic Malignant Transformation
Histology: Composed of differentiated tissues representing one or more embryonic germ cell layers:
Ectoderm: Keratinizing squamous epithelium, brain tissue, teeth, hair follicles.
Mesoderm: Mature hyaline cartilage, bone, smooth muscle, adipose tissue.
Endoderm: Bronchial respiratory epithelium, mucin-secreting intestinal glands.
Mature vs Immature: Mature teratoma contains fully differentiated adult-like tissues; immature teratoma contains primitive, fetal/embryonic blastema. In postpubertal males, both mature and immature teratomas are biologically malignant and capable of metastasis.
Chemo-Resistance & Radio-Resistance: Teratomatous elements do not undergo apoptosis in response to cisplatin-based chemotherapy or radiation therapy; they can ONLY be eradicated by complete surgical extirpation .
Malignant Somatic Transformation: In approximately 2% to 3% of cases, teratomatous elements undergo clonal malignant dedifferentiation into non-germ cell somatic malignancies, such as rhabdomyosarcoma, liposarcoma, enteric adenocarcinoma, squamous cell carcinoma, or embryonic-type neuroectodermal tumours (formerly PNET). Somatic-type malignancies respond poorly to standard germ cell chemotherapy; complete resection can be curative when feasible, with specialist histology-directed treatment for unresectable disease.
2. Stage I NSGCTT: Risk Stratification by Lymphovascular Invasion (LVI)
Stage I NSGCTT has no nodal or distant metastases; the primary may have local extension (pT1–pT4), post-orchiectomy serum markers normalize according to expected clearance curves (AFP half-life 5–7 days; beta-hCG 24–36 hours), and staging CT CAP shows no lymphadenopathy or visceral metastases.
The Dominant Prognostic Factor: Lymphovascular Invasion (LVI)
Extensive prospective multicenter trials have established that Lymphovascular Invasion (LVI) —the presence of tumour cells inside intratumoural or peritumoural endothelial-lined lymphatic channels or blood vessels—is the single most powerful, independent predictor of occult retroperitoneal micrometastases:
LVI-Negative: The risk of occult retroperitoneal metastases and subsequent clinical relapse is approximately 14% to 15% (85% are permanently cured by orchiectomy alone).
LVI-Positive: The risk of occult retroperitoneal micrometastases and subsequent relapse jumps to approximately 45% to 50% .
LVI and anatomical stage are related but not identical: pT1 is stage IA; pT2–pT4 is stage IB, and local invasion can yield pT2 even without LVI.
Secondary Risk Factors: A high percentage of embryonal carcinoma (>50%) and pathological T-stage (pT2–pT4) further augment risk, but LVI remains the primary guideline-defining variable.
3. Clinical Management of Stage I NSGCTT: Surveillance, Adjuvant BEP & RPLND
Following radical inguinal orchiectomy and verification of marker normalization, management pathways diverge based on LVI status:
Management of Low-Risk Stage I NSGCTT (LVI-Negative)
Active Surveillance (Preferred Standard per EAU Guidelines):
Protocol: EAU minimum surveillance uses markers/review four times in each of years 1–2, twice in year 3, and one to two times yearly in years 4–5. Abdominopelvic MRI/CT is twice in year 1, at 24 months, with 36/60-month imaging discussed; LVI-positive patients may need extra 18-month imaging. Include guideline chest imaging.
Rationale: Since 85% of men are already cured, surveillance protects the vast majority from the physical and toxic burdens of chemotherapy or surgery. Relapses require stage- and IGCCCG-adapted treatment, commonly three BEP cycles for good-risk disease; overall stage I cancer-specific survival is approximately 99% .
Adjuvant Chemotherapy (1x BEP): An alternative for men unwilling or unsuitable for surveillance. Primary nerve-sparing RPLND has a limited expert-centre role, particularly when chemotherapy is contraindicated and surveillance unacceptable, or with teratoma containing somatic-type malignancy.
Management of LVI-Positive Stage I NSGCTT
Adjuvant Chemotherapy with 1 Cycle of BEP (Discuss Alongside Surveillance):
Evidence: Landmark prospective trials by the German Testicular Cancer Study Group demonstrated that 1 cycle of BEP (bleomycin 30 mg days 1, 8, 15; etoposide 100 mg/m2 days 1–5; cisplatin 20 mg/m2 days 1–5) reduces the 2-year relapse rate from ~50% down to 1.6% to 2.3% .
Toxicity Profile: One cycle limits cumulative exposure compared with multi-cycle chemotherapy but can cause serious acute toxicity, including febrile neutropenia, and gonadal, pulmonary or renal effects. Very long-term cardiovascular and second-cancer risks are not fully defined; discuss sperm banking and follow-up.
Active Surveillance: A standard option after counselling about relapse risk approaching 50% and adherence to follow-up. Relapse requires stage-adapted treatment rather than an automatic fixed regimen.
Primary Nerve-Sparing RPLND: Resects primary retroperitoneal landing zones. If pathological nodes are negative (pN0), recurrence is <10%; if nodal metastases are identified, discuss surveillance or up to two adjuvant BEP cycles according to pathology and relapse risk; resected teratoma alone does not require chemotherapy. However, primary RPLND is invasive, carries a risk of retrograde ejaculation if sympathetic fibers are damaged, and has largely been superseded by 1x BEP in European practice.
4. Metastatic NSGCTT & The Complete IGCCCG Risk Classification
For marker-negative equivocal nodes <2 cm, repeat imaging after about six weeks. Confirmed stage IIA NSGCT with normal markers generally warrants expert nerve-sparing RPLND , whereas marker-positive IIA/B requires IGCCCG-adapted chemotherapy. For disseminated disease, the International Germ Cell Cancer Collaborative Group (IGCCCG) consensus classification categorizes patients into three distinct prognostic tiers that dictate first-line induction chemotherapy:
1. Good Risk NSGCTT (56% of metastatic cases)
Criteria (ALL must be met):
- Primary tumour origin: Testicular or retroperitoneal primary, AND
- Absence of non-pulmonary visceral metastases (NPVM) (pulmonary metastases are permitted!), AND
Markers below intermediate-risk thresholds (S0 or S1): AFP < 1,000 ng/mL, beta-hCG < 5,000 IU/L, and LDH < 1.5 × ULN.
Prognosis: Updated five-year PFS is ~90% ; overall survival is ~96% .
Standard Chemotherapy: 3 cycles of BEP , or 4 cycles of EP when bleomycin is contraindicated.
2. Intermediate Risk NSGCTT (28% of metastatic cases)
Criteria (ALL must be met):
- Primary tumour origin: Testicular or retroperitoneal primary, AND
- Absence of non-pulmonary visceral metastases (NPVM) , AND
Intermediate Serum Markers (S2): AFP 1,000 to 10,000 ng/mL, OR beta-hCG 5,000 to 50,000 IU/L, OR LDH 1.5 to 10 × ULN.
Prognosis: Updated five-year PFS is ~78% ; overall survival is ~89% .
Standard Chemotherapy: 4 cycles of BEP , or 4 cycles of VIP with G-CSF when bleomycin is contraindicated.
3. Poor Risk NSGCTT (16% of metastatic cases)
Criteria (ANY ONE of the following features):
- Primary tumour origin: Primary Mediastinal Non-Seminomatous Germ Cell Tumour (PMNSGCT) , OR
- Presence of non-pulmonary visceral metastases (NPVM) (e.g., liver, bone, brain), OR
Poor Serum Markers (S3): AFP > 10,000 ng/mL, OR beta-hCG > 50,000 IU/L, OR LDH > 10 × ULN.
Prognosis: In the updated IGCCCG cohort, five-year PFS is ~54% and overall survival ~67% ; outcomes vary within the group.
Standard Chemotherapy: 4 cycles of BEP (or 4 cycles of VIP [etoposide, ifosfamide, cisplatin] with G-CSF if bleomycin is contraindicated).
5. Post-Chemotherapy Residual Masses & The Role of Surgery
Following completion of first-line chemotherapy, repeat cross-sectional CT CAP and serum markers are performed to assess response.
The Mandatory Surgical Rule for NSGCTT
Whenever post-chemotherapy cross-sectional imaging reveals a residual retroperitoneal lymph node mass >1.0 cm in transaxial long axis after first-line chemotherapy and markers are normal or normalizing , surgical excision via Post-Chemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) is MANDATORY .
Histological Distribution of Resected Residual Tissue
Histology varies among series and prior regimens. Traditional post-chemotherapy surgical series report approximately:
40% to 50%: Fibrosis, necrotic cellular debris, and acellular xanthogranulomatous tissue.
35% to 40%: Mature Teratoma (benign-appearing differentiated tissues with malignant potential).
10% to 15%: Viable Active Malignant Germ Cell Carcinoma .
Growing Teratoma Syndrome & Somatic Transformation
Because cytotoxic chemotherapy destroys the chemosensitive malignant cells (embryonal, yolk sac, choriocarcinoma) while sparing the chemo-resistant teratoma, teratomatous cells can proliferate post-chemotherapy:
Growing Teratoma Syndrome: Enlarging masses during or after chemotherapy with normalized AFP/hCG suggest this syndrome; the resected lesion must show mature teratoma without viable malignant germ cell elements to establish it. Left untreated, growing teratomas compress the vena cava, aorta, and ureters, causing bilateral hydronephrosis, intestinal obstruction, and vascular thrombosis.
Malignant Transformation: Teratoma cells left in situ can develop somatic-type malignancy, such as adenocarcinoma or sarcoma. Resectable disease may still be curable; refer for specialist assessment.
Caution
PET Cannot Select NSGCTT Residual Masses for Observation: Unlike in seminoma, 18F-FDG PET-CT is strictly NOT recommended in non-seminoma. Mature teratoma has low metabolic glucose turnover and is PET-negative . A negative PET scan cannot distinguish mature teratoma from necrosis; relying on PET results would leave life-threatening teratoma unexcised in up to 40% of patients. Surgical resection remains mandatory for all residual masses > 1 cm regardless of PET findings.
6. Surgical Principles of PC-RPLND & Consolidation Chemotherapy
PC-RPLND is an extensive, technically challenging retroperitoneal procedure requiring referral to specialized high-volume tertiary centers:
Dissection Templates: A full bilateral template extends from the renal arteries to the bifurcation of the common iliac arteries, clearing the paracaval, precaval, interaortocaval, preaortic, and para-aortic nodal basins. Bilateral nerve-sparing RPLND is standard when feasible. A modified ipsilateral template may be considered for selected residuals <5 cm confined to one side on both pre- and post-chemotherapy imaging. Removing only the visible mass (lumpectomy) is inadequate.
Nerve-Sparing Techniques: Meticulous identification and preservation of the postganglionic sympathetic chains (L1–L3 lumbar splanchnic nerves) and the hypogastric plexus improves the chance of antegrade ejaculation, but preservation depends on disease extent and must not compromise complete resection.
Adjacent Vascular Resection: Complex adherent or invasive masses may require prosthetic aortic reconstruction, caval resection, or unilateral nephrectomy.
Adjuvant Consolidation Chemotherapy: Necrosis or teratoma alone requires no further chemotherapy. With incompletely resected viable cancer, two cisplatin-based cycles may be considered in selected patients. Completely resected, low-volume viable cancer—particularly <10% in an initially good-risk patient—may be observed. A >10% finding does not automatically mandate two TIP cycles.
IGCCCG Risk Classification & NSGCTT Clinical Management Algorithm
IGCCCG Risk Group Defining Features (NSGCTT) Chemotherapy Regimen Post-Chemotherapy Management Pathway
Good Risk (updated 5-yr OS ~96%) Testis/retroperitoneal primary, no non-pulmonary visceral metastases; all AFP <1,000, hCG <5,000, LDH <1.5× ULN 3x BEP ; 4x EP if bleomycin contraindicated After first-line treatment, resect residual masses >1 cm in transaxial long axis when markers normalize or are normalizing. For complete response/<1 cm, discuss surveillance versus selected surgery.
Intermediate Risk (updated 5-yr OS ~89%) Testis/retroperitoneal primary, no non-pulmonary visceral metastases; highest marker category S2 4x BEP ; 4x VIP with G-CSF if bleomycin contraindicated Same residual-mass pathway; FDG PET cannot exclude teratoma and is not recommended for restaging.
Poor Risk (updated 5-yr OS ~67%) Any: mediastinal primary, non-pulmonary visceral metastases, or S3 markers 4x BEP ; 4x VIP with G-CSF if bleomycin contraindicated Expert-centre residual surgery; consolidation depends on completeness of resection, viable cancer and initial risk, not an automatic >10%-then-TIP rule.
Stage IA pT1 N0 M0 S0; LVI-negative Surveillance preferred when feasible; 1x BEP alternative Relapse risk ~15%; overall stage I survival ~99% with appropriate treatment of relapse.
LVI-Positive Stage I Usually pT2 N0 M0 S0; stage IB can also arise from local invasion without LVI Discuss 1x BEP or surveillance LVI raises relapse risk towards 50%; one BEP cycle reduces it to about 2–3%, with toxicity counselling.